Table 3.
Univariate analysis of PFS and OS with platinum/pemetrexed+/antiangiogenic agent (A), ICPi (B) and OS since diagnosis of malignant pleural mesothelioma (C) by the Cox proportional-hazards regression model.
| A | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| Parameter | HR | 95% HR CI | p value | HR | 95% HR CI | p value | ||
| Platinum/pemetrexed+/-antiangiogenic agent | ||||||||
| Age | 1.01 | 0.99 | 1.04 | 0.25 | 1.03 | 0.99 | 1.07 | 0.08 |
| Sex (male vs female) | 2.64 | 0.88 | 7.78 | 0.08 | 3.63 | 0.88 | 14.98 | 0.07 |
| Histology (sarcomatoid vs epithelioid) | 13.02 | 2.01 | 84.30 | 0.007 | 11.22 | 1.84 | 68.44 | 0.008 |
| Histology (biphasic vs epithelioid) | 12.12 | 2.02 | 72.83 | 0.006 | 5.62 | 1.04 | 30.26 | 0.04 |
| No BAP1 mutation/not tested vs BAP1 mutation present |
0.99 | 0.40 | 2.42 | 0.97 | 1.44 | 0.46 | 4.45 | 0.53 |
| ECOG PS at chemotherapy initiation (2-4 vs 0/1) |
10.48 | 0.65 | 167.75 | 0.10 | 3.41 | 0.54 | 21.41 | 0.19 |
| EORTC prognostic scale (poor risk vs good-risk) |
8.96 | 2.01 | 39.88 | 0.004 | 9.33 | 2.13 | 40.83 | 0.003 |
| CALGB prognostic scale (3/4 vs 1/2) | 1.07 | 0.39 | 2.93 | 0.90 | 2.08 | 0.64 | 6.82 | 0.23 |
| CALGB prognostic scale (5/6 vs 1/2) | 1.49 | 0.33 | 6.78 | 0.60 | 2.34 | 0.44 | 12.45 | 0.32 |
| B | ICPi | |||||||
| Age | 0.97 | 0.92 | 1.03 | 0.37 | 0.95 | 0.89 | 1.03 | 0.21 |
| Sex (male vs female) | 0.86 | 0.22 | 3.32 | 0.83 | 0.96 | 0.21 | 4.42 | 0.96 |
| Histology (biphasic vs epithelioid) | 12.40 | 1.17 | 131.77 | 0.04 | 7.14 | 0.99 | 51.53 | 0.05 |
| No BAP1 mutation/not tested vs BAP1 mutation present |
0.44 | 0.09 | 2.08 | 0.30 | 1.07 | 0.23 | 4.92 | 0.93 |
| ECOG PS at ICPi initiation (2-4 vs 0/1) |
3.56 | 0.47 | 27.19 | 0.22 | 2.21 | 0.31 | 15.93 | 0.43 |
| EORTC prognostic scale (poor risk vs good-risk) |
12.96 | 0.81 | 207.57 | 0.07 | 12.41 | 0.77 | 199.35 | 0.07 |
| CALGB prognostic scale (3/4 vs 1/2) | 1.92 | 0.41 | 9.01 | 0.41 | 3.61 | 0.43 | 30.23 | 0.24 |
| CALGB prognostic scale (5/6 vs 1/2) | 2.63 | 0.28 | 25.12 | 0.40 | 1.20 | 0.10 | 14.51 | 0.88 |
| C | OS since diagnosis | |||||||
| Age | 1.02 | 0.99 | 1.05 | 0.07 | 1.02 | |||
| Sex (male vs female) | 2.93 | 1.11 | 7.75 | 0.03 | ||||
| Histology (sarcomatoid vs epithelioid) | 13.98 | 2.68 | 73.01 | 0.002 | ||||
| Histology (biphasic vs epithelioid) | 3.24 | 0.79 | 13.32 | 0.10 | ||||
| No BAP1 mutation/not tested vs BAP1 mutation present |
1.56 | 0.55 | 4.41 | 0.40 | ||||
| ECOG PS at diagnosis (2-4 vs 0/1) |
3.53 | 1.11 | 11.19 | 0.03 | ||||
| Surgery (EPP/decortication) vs none | 0.42 | 0.14 | 1.19 | 0.10 | ||||
| Radiotherapy vs none | 0.77 | 0.36 | 1.67 | 0.51 | ||||
| Platinum-based chemotherapy vs none | 1.54 | 0.57 | 4.16 | 0.39 | ||||
| ICPi vs none | 0.80 | 0.37 | 1.76 | 0.58 | ||||
| EORTC prognostic scale (poor risk vs good-risk) |
2.80 | 1.19 | 6.59 | 0.02 | ||||
| CALGB prognostic scale (3/4 vs 1/2) | 1.55 | 0.63 | 3.83 | 0.34 | ||||
| CALGB prognostic scale (5/6 vs 1/2) | 1.91 | 0.49 | 7.53 | 0.35 | ||||
BAP1, BRCA1 associated protein-1; CALGB, Cancer and Leukemia Group B; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status score; EORTC, European Organization for Research and Treatment of Cancer; EPP, extra-pleural pneumonectomy; HR, hazard ratio; ICPi, immune check-point inhibitors; OS, median overall survival; PFS, median progression-free survival.